# Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease

> **NCT07415018** · NA · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Leptomeningeal Disease

## Interventions

- **PROCEDURE:** MRI Scan
- **DRUG:** VUEWAY
- **DRUG:** Gadavist

## Key facts

- **NCT ID:** NCT07415018
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-22
- **Primary completion:** 2027-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07415018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07415018, "Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07415018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*